Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSUT2 small interfering RNA
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
**MSUT2 small interfering RNA** is an investigational RNA interference therapeutic concept designed to reduce expression of **mammalian suppressor of tauopathy 2**, an RNA-binding protein implicated in tau-mediated neurodegeneration. Preclinical work indicates that lowering MSUT2 can mitigate tau toxicity, reduce tau pathology, and improve neurobehavioral outcomes in tauopathy models, supporting development interest for **Alzheimer's disease and related tauopathies**. The therapeutic mechanism is sequence-specific post-transcriptional silencing of **MSUT2 messenger RNA**, leading to decreased MSUT2 protein levels; however, the available public information appears to describe a **research-stage siRNA approach or platform concept rather than a clearly identified named clinical drug candidate**.
- Other names
- MSUT2 siRNAMSUT-2 siRNAMSUT 2 siRNAMSUT2 small interfering RNAMSUT-2 small interfering RNAMSUT 2 small interfering RNA
02
Targets
MSUT2 (Mammalian suppressor of tauopathy 2)
Beyond the preview
Go deeper on MSUT2 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSUT2 small interfering RNA.